Published online May 16, 2023. doi: 10.12998/wjcc.v11.i14.3176
Peer-review started: February 27, 2023
First decision: March 10, 2023
Revised: March 24, 2023
Accepted: April 12, 2023
Article in press: April 12, 2023
Published online: May 16, 2023
Processing time: 78 Days and 1.7 Hours
Follicular lymphoma (FL) is a B-cell lymphoma that originates at the germinal center and has a low malignancy rate.
To gain a deeper understanding of the clinical characteristics, efficacy, and prognostic factors of FL in China and to provide guidance for clinical diagnosis and treatment, we retrospectively analyzed the clinical data of 49 patients with FL who were diagnosed and treated at our hospital in recent years.
This study aimed to explore the clinical features, curative effects, and prognostic factors of FL.
The medical records of 49 patients with FL admitted to the Ningbo First Hospital from June 2010 to June 2021 were retrospectively reviewed to compare the curative effects of different therapeutic schemes and analyze the related prognostic factors.
The age at onset in the 49 patients ranged from 24 to 76 years, with a median age of 51 years. The male:female ratio was 1.6:1. No significant difference was noted in the curative effect between the non-chemotherapy, combined chemotherapy, and other chemotherapy regimen groups. Hemoglobin (Hb) level < 120 g/L, Ki-67 value >50%, bone marrow involvement, and clinical stages III–IV were associated with a poor prognosis. However, the influence of the other indicators on prognosis was not statistically significant. Risk grouping was performed using the Follicular Lymphoma International Prognosis Index. The results showed that 24.5%, 40.8%, and 34.7% of patients were in the low-, moderate-, and high-risk groups, respectively. According to the survival analysis results, the survival rate of patients was lower in the high-risk group than in the other two groups.
FL mainly occurs in middle-aged or older men who mainly present with lymph node and bone marrow involvement. Hb level, Ki-67 value, bone marrow involvement, and clinical stage can be used for prognostic estimation.
To analyze the clinical characteristics, efficacy, prognosis, and survival factors of 49 patients in order to improve clinicians' understanding of the disease and provide guidance for clinical diagnosis and treatment.